These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24696308)

  • 1. Introducing a new group B meningococcus vaccine.
    Isaacs D; McVernon J
    BMJ; 2014 Apr; 348():g2415. PubMed ID: 24696308
    [No Abstract]   [Full Text] [Related]  

  • 2. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1428-9. PubMed ID: 25396230
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meningococcus B vaccine: a new tool against invasive bacteric diseases].
    Carlino C; Zaratti L; Franco E
    Ig Sanita Pubbl; 2013; 69(3):363-75. PubMed ID: 23903040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.
    Giuliani MM; Biolchi A; Serruto D; Ferlicca F; Vienken K; Oster P; Rappuoli R; Pizza M; Donnelly J
    Vaccine; 2010 Jul; 28(31):5023-30. PubMed ID: 20493284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence for political manipulation regarding the new group B meningococcus vaccine.
    Moxon ER; Black S
    BMJ; 2014 May; 348():g2929. PubMed ID: 24812090
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No conspiracy regarding recommendation for a group B meningococcus vaccine.
    Pollard AJ; Riordan A; Ramsay M
    BMJ; 2014 May; 348():g2859. PubMed ID: 24812089
    [No Abstract]   [Full Text] [Related]  

  • 13. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 14. [Group B meningococcal invasive infections: an unresolved public health problem].
    Crisinel PA; Posfay-Barbe KM
    Rev Med Suisse; 2011 Feb; 7(283):447-50. PubMed ID: 21452513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Brief: New meningococcal serogroup B vaccination recommendations.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):191-192. PubMed ID: 33443493
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 18. Meningococcal B vaccine development and evaluation of efficacy.
    van Alphen L; van den Dobbelsteen G
    Hum Vaccin; 2008; 4(2):158-61. PubMed ID: 18388494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.